CHEMOPREVENTION FOR PROSTATE CANCER IN PATIENTS WITH BENIGN PROSTATE HYPERPLASIA WITH ELEVATED PROSTATE-SPECIFIC ANTIGEN LEVELS

The paper gives the comparative results of chemoprevention against prostate cancer (PC) in 189 patients with benign prostate hyperplasia with a prostate-specific antigen (PSA) level of 2.5 to 10.0 ng/ml during 4‑year combined (avodart + omnic) or monotherapy with either drug. Biopsy revealed PC in 1...

Full description

Bibliographic Details
Main Authors: Yu. I. Kushniruk, V. A. Yarosh, M. D. Dyachuk
Format: Article
Language:Russian
Published: ABV-press 2014-07-01
Series:Onkourologiâ
Subjects:
Online Access:https://oncourology.abvpress.ru/oncur/article/view/139